Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1162-1169

  Klatte, Tobias ^a   Pantuck, Allan J ^a   Said, Jonathan W ^a   Seligson, David B ^a   Rao, Nagesh P ^a   Larochelle, Jeffrey C ^a   Shuch, Brian ^a   Zisman, Amnon ^a,b   Kabbinavar, Fairooz F ^a   Belldegrun, Arie S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME 5P; CHROMOSOME 9P; CHROMOSOME LOSS; CONTROLLED STUDY; CYTOGENETICS; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; NECROSIS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; AGED; CHEMISTRY; CHROMOSOME ABERRATION; GENETICS; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, RENAL CELL; CHROMOSOME ABERRATIONS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 63149193393     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1229     Document Type: Article

References (38)

1. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183:131-3.
2. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005:23: 2763-71.
3. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003:27:612-24.
4. LinehanWM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007:13:671 -9s.
5. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 1998;20:66-9.
6. Fischer J, Palmedo G, von Knobloch R, et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 1998; 17: 733-9.
7. Launonen V, Vierimaa 0, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001;98: 3387-92.
8. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-10.
9. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537-44.
10. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinet
11. ics and patient survival in 66 cases. Hum Pathol 2001; 32:590-5.
12. Gunawan B, von HA, FritschT, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 2003;63:6200-5.
13. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007;69:230-5.
14. Méjean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol 2003;170:764-7.
15. Leroy X, Zini L, Leteurtre E, et al. Morphologic sub- typing of papillary renal cell carcinoma: correlation with prognosis and differential expression of MUC1 between the two subtypes. Mod Pathol 2002;15: 1126-30.
16. Kovacs G. Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am J Pathol 1989;134:27-34.
17. Sika-Paotonu D, Bethwaite PB, McCredie MR, William JordanT, Delahunt B. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol 2006;30:1091 -6.
18. American Joint Committee on Cancer. Kidney. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p. 323-5.
19. Oken MM, Creech RH. Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
21. International Standing Committee on Human Cytogenetic Nomenclature. ISCN 2005: an international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic. Basel; Farmington (CT): Karger; 2005.
22. Blute ML, Itano NB, Cheville JC, Weaver AL, Lohse CM, Zincke H. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol 2003;169:1276-81.
23. Dimarco DS, Lohse CM, Zincke H, Cheville JC, Blute ML. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to his tologic subtype compared with patients with solitary tumors after radical nephrectomy. Urology 2004;64: 462-7.
24. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005:104:511 -20.
25. Yang XJ. Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005;65:5628-37.
26. Stadler WM, Figlin RA, Ernstoff MS, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). [abstr]. J Clin Oncol Annu Meet Proc Part I 2007:25:5036.
27. Seligson DB, Pantuck AJ, Liu X, et al. Epithelial cell adhesion molecule (KSA) expression: pathobiol- ogy and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 2004; 10:2659-69.
28. Visapää H, Bui M, Huang Y, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003;61:845-50.
29. Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998;153:1467-73.
30. Sanders ME, Mick R, Tomaszewski JE, Barr FG.
31. Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol 2002;161:997-1005.
32. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 1991;3:249-55.
33. Yao M, Yoshida M, KishidaT, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569-75.
34. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. 0ncogene1999;18:2343-50.
35. Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto- oncogene. Cancer Res 1998;58:1719-22.
36. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
37. Miyata Y, Kanetake H, Kanda S. Presence of phos-phorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res 2006:12:4876-81.
38. Natali PG, Prat M, Nicotra MR, et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 1996;69:212-7.